Medizinische Veröffentlichungen

Med. Veröffentlichungen im Bereich Rheumatologie



Datum Verlag Titel Verfasser Download
02.06.2017 Arthritis care & research Valuing treatment with infliximab for ankylosing spondylitis using a willingness-to-pay approach Webers C., Essers I., van Tubergen A., Braun J., Heldmann F., Baraliakos X., Boonen A.
07.04.2017 Arthritis research & therapy Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis - The TryCort-study Kiltz U, von Zabern C, Baraliakos X, Heldmann F, Mintrop B, Sarholz m, Krause D, Dybowski F, Kalthoff L, Braun J
Februar 2017 Zeitschrift für Rheumatologie Memorandum Rheumatologie aktuell - Therapieprinzip der IL-17_Inhibition in Empfehlungen aufgenommen Heldmann, F.
Dezember 2016 Journal of Rheumatology Quantification of Bone Marrow Edema by Magnetic Resonance Imaging Only Marginally Reflects Clinical Neck Pain Evaluation in Rheumatoid Arthritis and Ankylosing Spondylitis Baraliakos X, Heldmann F, Callhoff J, Suppiah R, McQueen FM, Krause D, Klink C, Schmitz-Bortz E, Igelmann M, Kalthoff L, Kiltz U, Schmuedderich A, Braun J.
Juli 2016 RMD open Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction Baraliakos X, Heldmann F, van den Bosch F, Burmester G, Gaston H, van der Horst-Bruinsma IE, Krause A, Schmidt R, Schneider M, Sieper J, Andermann B, van Tubergen A, Witt M, Braun J.
März/ April 2016 Clinical and experimental rheumatology Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety Heldmann F, Baraliakos X, Kiltz U, Brandt J, van der Horst-Bruinsma IE, Landewé R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Gaston H, Gruenke M, Witt M, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Braun J.
Februar 2016 Zeitschrift für Rheumatologie Do we still need clinical studies in rheumatology? Henkemeier U, Alten R, Bannert B, Baraliakos X, Behrens F, Heldmann F, Kiltz U, Köhm M, König R, Leipe J, Müller-Ladner U, Rech J, Riechers E, Rubbert-Roth A, Schmidt RE, Schulze-Koops H, Specker C, Tausche AK, Wassenberg S, Witt M, Witte T, Zernicke J, Burkhardt H.
17.11.2015 RMD open Do patients with ankylosing spondylitis adapt to their disease? Evidence from a 'then-test' in patients treated with TNF inhibitors Essers I, van Tubergen A, Heldmann F, Baraliakos X, Braun J, Kiltz U, Boonen A.
November 2016 Arthritis care & research Longitudinal Analyses of Presenteeism and Its Role as a Predictor of Sick Leave in Patients With Ankylosing Spondylitis Tran-Duy A, Nguyen TT, Thijs H, Baraliakos X, Heldmann F, Braun J, Boonen A.
2015 Expert review of clinical immunology Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes Braun J, Kiltz U, Sarholz M, Heldmann F, Regel A, Baraliakos X.
März 2015 Expert opinion on emerging drugs Emerging drugs for the treatment of axial and peripheral spondyloarthritis Braun J, Kiltz U, Heldmann F, Baraliakos X.
Januar 2015 Journal of Rheumatology Classification and diagnosis of axial spondyloarthritis--what is the clinically relevant difference? Braun J, Baraliakos X, Kiltz U, Heldmann F, Sieper J.
Oktober 2014 Zeitschrift für Rheumatologie SAPHO syndrome Heldmann F, Kiltz U, Baraliakos X, Braun J.
Mai 2014 Expert opinion in investigational drugs Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis Braun J, Baraliakos X, Heldmann F, Kiltz U.
Dezember 2013 Der Internist What is ascertained in the therapy of axial spondyloarthritis? Braun J, Baraliakos X, Heldmann F, Kiltz U.
Juli/August 2013 Clinical and experimental rheumatology Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease Baraliakos X, Kiltz U, Heldmann F, Sieper J, Braun J.
Oktober 2014 annals of the rheumatic diseases Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, Van den Bosch F, Breban M, Burmester G, Dougados M, Emery P, Gaston H, Grunke M, Van Der Horst-Bruinsma IE, Landewé R, Leirisalo-Repo M, Sieper J, De Vlam K, Pappas D, Kiltz U, Van Der Heijde D, Braun J.
2013 Arthritis research & therapy Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, Sieper J.
August 2013 Arthritis and rheumatism Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare. Haibel H, Heldmann F, Braun J, Listing J, Kupper H, Sieper J.
Juni 2014 annals of the rheumatic diseases High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. Baraliakos X, Baerlecken N, Witte T, Heldmann F, Braun J.
Februar 2013 annals of the rheumatic diseases One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Haug-Rost I, Braun J, Sieper J.
Mai 2012 current opinion in rheumatology Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives? Kiltz U, Heldmann F, Baraliakos X, Braun J.
Februar 2012 Zeitschrift für Rheumatologie Practical problems by implementation of vaccination recommendations Fendler C, Saracbasi, E.; Dybowski, F.; Heldmann, F.; Braun, J.